arrow
S

Sıla Akhan

kocaeli university
H指数:13
被引数:1,436

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cancer prevalence and prognosis among individuals living with HIV and AIDS in Turkey: Multicenter BUHASDER study

土耳其HIV和艾滋病感染者中癌症的患病率与预后:多中心BUHASDER研究

2025-12-010
PRE
Evaluation of the Efficacy of Tenofovir Alafenamide in Patients with Low-Level Viremia Under Chronic Hepatitis B Treatment

评估替诺福韦艾拉酚胺在低水平病毒血症慢性乙型肝炎治疗患者中的疗效

2025-11-040
OAAI
Long-term metabolic and safety profiles of tenofovir alafenamide and tenofovir disoproxil fumarate in ART-naive people living with HIV: a multicenter retrospective study using a mixed-effects model

替诺福韦艾拉酚胺和替诺福韦二吡呋酯在ART初治的HIV感染者中的长期代谢和安全性特征:一项采用混合效应模型的回顾性多中心研究

2025-10-150
OAAI
Predictive Factors for HBsAg Seroconversion Following Acute Hepatitis B Virus Infection: A Multicenter BUHASDER Study

急性乙型肝炎病毒感染后HBsAg血清学转换的预测因素:一项多中心BUHASDER研究

2025-08-290
OA
Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19

吸入用Aviptadil是治疗COVID-19导致肺损伤恢复的新希望

2025-01-270
OA
The impact of previous SARS-CoV-2 infection on post-vaccine adverse events in individuals vaccinated with TURKOVAC or CoronaVac -inactivated COVID-19 vaccines

既往SARS-CoV-2感染对接种TURKOVAC或CoronaVac灭活新型冠状病毒肺炎疫苗个体的疫苗后不良事件的影响

2024-06-260
OAAI
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

灭活全病毒新型冠状病毒疫苗(科罗娜疫苗)的efficacy和安全性:土耳其一项双盲、随机、安慰剂对照的Ⅲ期临床试验中期结果

LANCET
IF88.5
2021-07-01722
OAAI
Noninvasive models to predict liver fibrosis in patients with chronic hepatitis B: a study from Turkey
2017-01-010
PREAI